{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:35Z","timestamp":1794047495201,"version":"4.8.0"},"reference-count":47,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Follicular lymphoma (FL) is an indolent B-cell lymphoma with a heterogenous disease course, and patients may not require immediate treatment upon diagnosis. Scrutiny of its microenvironment may provide key insights into lymphomagenesis and enhancement of therapeutic options. We analyzed the T-cell composition of a large, well-annotated follicular hyperplasia (FH; N=43) cohort utilizing standardized high dimensionality flow cytometry (&gt;150,000 cells analyzed\/sample) and a novel reproducible analytical pipeline leading to identification of even minor T-cell subsets. This baseline reference set was compared to prospectively collected FL samples (N=91) from untreated patients (FL-UT) and patients with relapsed\/refractory disease (FL-RR). Compared to FH, both FL-UT and FL-RR specimens exhibited depletion of CD4+ and CD8+ na\u00efve subsets and were characterized by an immune suppressive microenvironment enriched in specific inhibitory T cells, along with exhausted memory T cells overexpressing varying combinations of immune checkpoint receptors. FL specimens showed enrichment of T-follicular regulatory cells (TFR) and two highly suppressive regulatory T-cell (T-reg) populations expressing TIGIT and CTLA4 (TC) and PD1, TIGIT, CTLA4, and TIM3 (PTCTi). FL-UT cases with either increased T-reg TC or increased T-follicular helper cells (TFH) showed reduced time to first treatment (&lt;\/= 3 months). Our study suggests that changes in the balance between TFR, T-reg and TFH may lead to greater tumor growth and identifies factors that are associated with earlier time to treatment in FL-UT. We also identified specific combinations of immune checkpoint receptors that may be used to target specific inhibitory T-cell subsets and regulatory cells in FL to increase anti-tumor immune response.<\/jats:p>","DOI":"10.3324\/haematol.2024.286383","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T03:42:04Z","timestamp":1738813324000},"page":"1808-1821","source":"Crossref","is-referenced-by-count":2,"title":["Deep immunophenotypic dissection and clinical impact of T cells in the follicular lymphoma microenvironment"],"prefix":"10.3324","volume":"110","author":[{"given":"Sary","family":"El Daker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Qualls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samida","family":"Beqaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Boiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatraman","family":"Seshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeyeon","family":"Baik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Roshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Galera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"77503","unstructured":"Swerdlow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. 2017."},{"key":"77504","doi-asserted-by":"crossref","unstructured":"Batlevi CL, Sha F, Alperovich A. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020; 10(7):74.","DOI":"10.1038\/s41408-020-00340-z"},{"key":"77505","doi-asserted-by":"crossref","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P. Follicular lymphoma international prognostic index. Blood. 2004; 104(5):1258-1265.","DOI":"10.1182\/blood-2003-12-4434"},{"key":"77506","doi-asserted-by":"crossref","unstructured":"Federico M, Bellei M, Marcheselli L. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009; 27(27):4555-4562.","DOI":"10.1200\/JCO.2008.21.3991"},{"key":"77507","doi-asserted-by":"crossref","unstructured":"Pastore A, Jurinovic V, Kridel R. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015; 16(9):1111-1122.","DOI":"10.1016\/S1470-2045(15)00169-2"},{"key":"77508","doi-asserted-by":"crossref","unstructured":"Bachy E, Maurer MJ, Habermann TM. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018; 132(1):49-58.","DOI":"10.1182\/blood-2017-11-816405"},{"key":"77509","doi-asserted-by":"crossref","unstructured":"Huet S, Tesson B, Jais JP. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 2018; 19(4):549-561.","DOI":"10.1016\/S1470-2045(18)30102-5"},{"key":"77510","doi-asserted-by":"crossref","unstructured":"Dave SS, Wright G, Tan B. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004; 351(21):2159-2169.","DOI":"10.1056\/NEJMoa041869"},{"key":"77511","doi-asserted-by":"crossref","unstructured":"Farinha P, Masoudi H, Skinnider BF. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005; 106(6):2169-2174.","DOI":"10.1182\/blood-2005-04-1565"},{"key":"77512","doi-asserted-by":"crossref","unstructured":"Carreras J, Lopez-Guillermo A, Roncador G. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol. 2009; 27(9):1470-1476.","DOI":"10.1200\/JCO.2008.18.0513"},{"key":"77513","doi-asserted-by":"crossref","unstructured":"Richendollar BG, Pohlman B, Elson P, Hsi ED. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Hum Pathol. 2011; 42(4):552-557.","DOI":"10.1016\/j.humpath.2010.08.015"},{"key":"77514","doi-asserted-by":"crossref","unstructured":"Laurent C, M\u00fcller S, Do C. Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood. 2011; 118(20):5371-5379.","DOI":"10.1182\/blood-2011-04-345777"},{"key":"77515","doi-asserted-by":"crossref","unstructured":"Sugimoto T, Watanabe T. Follicular lymphoma: the role of the tumor microenvironment in prognosis. J Clin Exp Hematop. 2016; 56(1):1-19.","DOI":"10.3960\/jslrt.56.1"},{"key":"77516","doi-asserted-by":"crossref","unstructured":"Glas AM, Knoops L, Delahaye L. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol. 2007; 25(4):390-398.","DOI":"10.1200\/JCO.2006.06.1648"},{"key":"77517","doi-asserted-by":"crossref","unstructured":"Radtke A, Postovalova E, Varlamova A. A multi-scale, multiomic atlas of human normal and follicular lymphoma lymph nodes. bioRxiv. 2022. Publisher Full Text|","DOI":"10.1158\/2643-3249.LYMPHOMA22-IA31"},{"key":"77518","doi-asserted-by":"crossref","unstructured":"Han G, Deng Q, Marques-Piubelli ML. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov. 2022; 3(5):428-443.","DOI":"10.1158\/2643-3230.BCD-21-0075"},{"key":"77519","doi-asserted-by":"crossref","unstructured":"Laurent C, Dietrich S, Tarte K. Cell crosstalk within lymphoma tumor microenvironment: follicular lymphoma as a paradigm. Blood. 2024; 143(12):1080-1090.","DOI":"10.1182\/blood.2023021000"},{"key":"77520","doi-asserted-by":"crossref","unstructured":"Am\u00e9-Thomas P, Tarte K. The yin and the yang of follicular lymphoma cell niches: role of microenvironment heterogeneity and plasticity. Semin Cancer Biol. 2014; 24:23-32.","DOI":"10.1016\/j.semcancer.2013.08.001"},{"key":"77521","doi-asserted-by":"crossref","unstructured":"Haebe S, Shree T, Sathe A. Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma. Blood. 2021; 137(21):2869-2880.","DOI":"10.1182\/blood.2020009855"},{"key":"77522","doi-asserted-by":"crossref","unstructured":"Grant SM, Lou M, Yao L, Germain RN, Radtke AJ. The lymph node at a glance - how spatial organization optimizes the immune response. J Cell Sci. 2020; 133(5):jcs241828.","DOI":"10.1242\/jcs.241828"},{"key":"77523","doi-asserted-by":"crossref","unstructured":"Hahne F, Khodabakhshi AH, Bashashati A. Per-channel basis normalization methods for flow cytometry data. Cytometry A. 2010; 77(2):121-131.","DOI":"10.1002\/cyto.a.20823"},{"key":"77524","unstructured":"McInnes L, Healy J, Melville J. Umap: uniform manifold approximation and projection for dimension reduction. arXiv. 2020. Publisher Full Text|"},{"key":"77525","doi-asserted-by":"crossref","unstructured":"Van Gassen S, Callebaut B, Van Helden MJ, Lambrecht BN, Demeester P, Dhaene T, Saeys Y. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A. 2015; 87(7):636-645.","DOI":"10.1002\/cyto.a.22625"},{"key":"77526","doi-asserted-by":"crossref","unstructured":"Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol. 2012; 12(3):191-200.","DOI":"10.1038\/nri3158"},{"key":"77527","doi-asserted-by":"crossref","unstructured":"Sage PT, Sharpe AH. T follicular regulatory cells in the regulation of B cell responses. Trends Immunol. 2015; 36(7):410-418.","DOI":"10.1016\/j.it.2015.05.005"},{"key":"77528","doi-asserted-by":"crossref","unstructured":"Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y. CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers (Basel). 2021; 13(6):1440.","DOI":"10.3390\/cancers13061440"},{"key":"77529","doi-asserted-by":"crossref","unstructured":"Banerjee H, Nieves-Rosado H, Kulkarni A. Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. Cell Rep. 2021; 36(11):109699.","DOI":"10.1016\/j.celrep.2021.109699"},{"key":"77530","doi-asserted-by":"crossref","unstructured":"Liu Z, McMichael EL, Shayan G. Novel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients. Clin Cancer Res. 2018; 24(18):4529-4538.","DOI":"10.1158\/1078-0432.CCR-17-1350"},{"key":"77531","doi-asserted-by":"crossref","unstructured":"Spasevska I, Sharma A, Steen CB. Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma. Blood Adv. 2023; 7(23):7216-7230.","DOI":"10.1182\/bloodadvances.2023010158"},{"key":"77532","doi-asserted-by":"crossref","unstructured":"Mulder TA, Wahlin BE, \u00d6sterborg A, Palma M. Targeting the immune microenvironment in lymphomas of B-cell origin: from biology to clinical application. Cancers (Basel). 2019; 11(7):915.","DOI":"10.3390\/cancers11070915"},{"key":"77533","doi-asserted-by":"crossref","unstructured":"Kim JH, Kim BS, Lee SK. Regulatory T cells in tumor microenvironment and approach for anticancer immunotherapy. Immune Netw. 2020; 20(1):e4.","DOI":"10.4110\/in.2020.20.e4"},{"key":"77534","doi-asserted-by":"crossref","unstructured":"Armengol M, Santos JC, Fern\u00e1ndez-Serrano M, Profit\u00f3s-Pelej\u00e0 N, Ribeiro ML, Rou\u00e9 G. Immune-checkpoint inhibitors in B-cell lymphoma. Cancers (Basel). 2021; 13(2):214.","DOI":"10.3390\/cancers13020214"},{"key":"77535","doi-asserted-by":"crossref","unstructured":"Jacobson CA, Chavez JC, Sehgal AR. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022; 23(1):91-103.","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"77536","doi-asserted-by":"crossref","unstructured":"Fowler NH, Dickinson M, Dreyling M. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022; 28(2):325-332.","DOI":"10.1038\/s41591-021-01622-0"},{"key":"77537","doi-asserted-by":"crossref","unstructured":"Budde LE, Assouline S, Sehn LH. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022; 40(5):481-491.","DOI":"10.1200\/JCO.21.00931"},{"key":"77538","doi-asserted-by":"crossref","unstructured":"Yang ZZ, Kim HJ, Villasboas JC. Mass cytometry analysis reveals that specific intratumoral CD4(+) T cell subsets correlate with patient survival in follicular lymphoma. Cell Rep. 2019; 26(8):2178-2193.e3.","DOI":"10.1016\/j.celrep.2019.01.085"},{"key":"77539","doi-asserted-by":"crossref","unstructured":"Mondello P, Fama A, Larson MC. Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer J. 2021; 11(7):130.","DOI":"10.1038\/s41408-021-00521-4"},{"key":"77540","doi-asserted-by":"crossref","unstructured":"Okeke EB, Uzonna JE. The pivotal role of regulatory T cells in the regulation of innate immune cells. Front Immunol. 2019; 10:680.","DOI":"10.3389\/fimmu.2019.00680"},{"key":"77541","doi-asserted-by":"crossref","unstructured":"Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood. 2006; 107(9):3639-3646.","DOI":"10.1182\/blood-2005-08-3376"},{"key":"77542","doi-asserted-by":"crossref","unstructured":"Joller N, Lozano E, Burkett PR. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 2014; 40(4):569-581.","DOI":"10.1016\/j.immuni.2014.02.012"},{"key":"77543","doi-asserted-by":"crossref","unstructured":"Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, Anderson AC. TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology. 2013; 2(4):e23849.","DOI":"10.4161\/onci.23849"},{"key":"77544","doi-asserted-by":"crossref","unstructured":"Fazilleau N, Aloulou M. Several follicular regulatory T cell subsets with distinct phenotype and function emerge during germinal center reactions. Front Immunol. 2018; 9:1792.","DOI":"10.3389\/fimmu.2018.01792"},{"key":"77545","doi-asserted-by":"crossref","unstructured":"Hao H, Nakayamada S, Tanaka Y. Differentiation, functions, and roles of T follicular regulatory cells in autoimmune diseases. Inflamm Regen. 2021; 41(1):14.","DOI":"10.1186\/s41232-021-00164-9"},{"key":"77546","doi-asserted-by":"crossref","unstructured":"Wing JB, Kitagawa Y, Locci M. A distinct subpopulation of CD25(-) T-follicular regulatory cells localizes in the germinal centers. Proc Natl Acad Sci U S A. 2017; 114(31):E6400-E6409.","DOI":"10.1073\/pnas.1705551114"},{"key":"77547","doi-asserted-by":"crossref","unstructured":"Yang ZZ, Grote DM, Xiu B. TGF-\u03b2 upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin\u2019s lymphoma. Leukemia. 2014; 28(9):1872-1884.","DOI":"10.1038\/leu.2014.84"},{"key":"77548","doi-asserted-by":"crossref","unstructured":"Shibamiya A, Miyamoto-Nagai Y, Koide S. The pathogenetic significance of exhausted T cells in a mouse model of mature B cell neoplasms. Cancer Immunol Immunother. 2023; 72(8):2635-2648.","DOI":"10.1007\/s00262-023-03447-x"},{"key":"77549","doi-asserted-by":"crossref","unstructured":"Yang ZZ, Grote DM, Ziesmer SC, Xiu B, Novak AJ, Ansell SM. PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival. Blood Cancer J. 2015; 5(2):e281.","DOI":"10.1038\/bcj.2015.1"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11931\/78066","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11931\/78630","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11931\/78066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:09Z","timestamp":1794046089000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286383","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}